172 related articles for article (PubMed ID: 33625722)
1. Effects of gadobutrol on background parenchymal enhancement and differential diagnosis between benign and malignant lesions in dynamic magnetic resonance imaging of the breast.
Tozaki M; Yabuuchi H; Goto M; Sasaki M; Kubota K; Nakahara H
Breast Cancer; 2021 Jul; 28(4):927-936. PubMed ID: 33625722
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of electric properties tomography (EPT) for differentiating benign from malignant breast lesions: comparison with standard dynamic contrast-enhanced MRI.
Mori N; Tsuchiya K; Sheth D; Mugikura S; Takase K; Katscher U; Abe H
Eur Radiol; 2019 Apr; 29(4):1778-1786. PubMed ID: 30255252
[TBL] [Abstract][Full Text] [Related]
3. Ultrafast Dynamic Contrast-Enhanced Breast MRI: Kinetic Curve Assessment Using Empirical Mathematical Model Validated with Histological Microvessel Density.
Mori N; Abe H; Mugikura S; Takasawa C; Sato S; Miyashita M; Mori Y; Pineda FD; Karczmar GS; Tamura H; Takahashi S; Takase K
Acad Radiol; 2019 Jul; 26(7):e141-e149. PubMed ID: 30269956
[TBL] [Abstract][Full Text] [Related]
4. Gadoteridol-enhanced MRI of the breast: can contrast agent injection rate impact background parenchymal enhancement?
Marzocca F; Moffa G; Landi VN; Panzironi G; Kirchin MA; Pediconi F; Galati F
Acta Radiol; 2022 Sep; 63(9):1173-1179. PubMed ID: 34323589
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of background parenchymal enhancement in breast contrast-enhanced ultrasound with Sonazoid
Haga M; Hirai T; Nakai T; Kobayashi T; Nakamura T; Marugami A; Ito T; Takewa M; Marugami N; Kichikawa K
J Med Ultrason (2001); 2020 Oct; 47(4):591-601. PubMed ID: 32989596
[TBL] [Abstract][Full Text] [Related]
6. Comparison of gadoteric acid and gadobutrol for detection as well as morphologic and dynamic characterization of lesions on breast dynamic contrast-enhanced magnetic resonance imaging.
Renz DM; Durmus T; Böttcher J; Taupitz M; Diekmann F; Huppertz A; Pfeil A; Maurer MH; Streitparth F; Bick U; Hamm B; Fallenberg EM
Invest Radiol; 2014 Jul; 49(7):474-84. PubMed ID: 24637587
[TBL] [Abstract][Full Text] [Related]
7. Background parenchymal enhancement on contrast-enhanced spectral mammography does not represent an influencing factor for breast cancer: A preliminary study.
Yu L; Wang Y; Xing D; Gong P; Chen Q; Lv Y
Medicine (Baltimore); 2020 Dec; 99(52):e23857. PubMed ID: 33350778
[TBL] [Abstract][Full Text] [Related]
8. Analysis of background parenchymal enhancement (BPE) on contrast enhanced spectral mammography compared with magnetic resonance imaging.
Luczynska E; Pawlak M; Piegza T; Popiela TJ; Heinze S; Dyczek S; Rudnicki W
Ginekol Pol; 2021; 92(2):92-97. PubMed ID: 33448005
[TBL] [Abstract][Full Text] [Related]
9. Effects of menstrual cycle on background parenchymal enhancement and detectability of breast cancer on dynamic contrast-enhanced breast MRI: A multicenter study of an Asian population.
Kamitani T; Yabuuchi H; Kanemaki Y; Tozaki M; Sonomura T; Mizukoshi W; Nakata W; Shimono T; Urano M; Yamano T; Kato F; Kuchiki M; Shiragami N; Yanagita H; Katsuda E; Kataoka M; Yamaguchi K; Horikoshi T; Gomi T; Nozaki M; Shiotani M; Amano M; Saigusa H; Sadaoka S; Kamiya H; Kubo M; Yamashita N; Yamamoto H; Honda H
Eur J Radiol; 2019 Jan; 110():130-135. PubMed ID: 30599849
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Association Between Menstrual Cycle Timing and Quantitative Background Parenchymal Enhancement on Breast MRI in Premenopausal Women.
He Y; Zhou J; Liu X; Wei Y; Ye S; Miao H; Liu H; Chen Z; Zhao Y; Wang M
Clin Breast Cancer; 2023 Oct; 23(7):e451-e457.e1. PubMed ID: 37640598
[TBL] [Abstract][Full Text] [Related]
11. MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
Lo Gullo R; Daimiel I; Rossi Saccarelli C; Bitencourt A; Sevilimedu V; Martinez DF; Jochelson MS; Morris EA; Reiner JS; Pinker K
Breast Cancer Res; 2020 Aug; 22(1):93. PubMed ID: 32819432
[TBL] [Abstract][Full Text] [Related]
12. Contrast-enhanced 3.0-T breast MRI for characterization of breast lesions: increased specificity by using vascular maps.
Schmitz AC; Peters NH; Veldhuis WB; Gallardo AM; van Diest PJ; Stapper G; van Hillegersberg R; Mali WP; van den Bosch MA
Eur Radiol; 2008 Feb; 18(2):355-64. PubMed ID: 17882425
[TBL] [Abstract][Full Text] [Related]
13. Gadobutrol-Enhanced Magnetic Resonance Imaging of the Breast in the Preoperative Setting: Results of 2 Prospective International Multicenter Phase III Studies.
Sardanelli F; Newstead GM; Putz B; Jirakova Trnkova Z; Trimboli RM; Abe H; Haverstock D; Rosenberg M
Invest Radiol; 2016 Jul; 51(7):454-61. PubMed ID: 26840494
[TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75).
Liu BP; Rosenberg M; Saverio P; Weon YC; Peters S; Ardellier FD; Boeckenhoff A; Endrikat J
AJR Am J Roentgenol; 2021 Nov; 217(5):1195-1205. PubMed ID: 34133205
[No Abstract] [Full Text] [Related]
15. Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer.
Wu S; Berg WA; Zuley ML; Kurland BF; Jankowitz RC; Nishikawa R; Gur D; Sumkin JH
Breast Cancer Res; 2016 Jul; 18(1):76. PubMed ID: 27449059
[TBL] [Abstract][Full Text] [Related]
16. Impact of background parenchymal enhancement levels on the diagnosis of contrast-enhanced digital mammography in evaluations of breast cancer: comparison with contrast-enhanced breast MRI.
Yuen S; Monzawa S; Gose A; Yanai S; Yata Y; Matsumoto H; Ichinose Y; Tashiro T; Yamagami K
Breast Cancer; 2022 Jul; 29(4):677-687. PubMed ID: 35220511
[TBL] [Abstract][Full Text] [Related]
17. Background parenchymal enhancement in pregnancy-associated breast cancer: a hindrance to diagnosis?
Taron J; Fleischer S; Preibsch H; Nikolaou K; Gruber I; Bahrs S
Eur Radiol; 2019 Mar; 29(3):1187-1193. PubMed ID: 30229271
[TBL] [Abstract][Full Text] [Related]
18. Contrast enhancement kinetics of normal breast parenchyma in dynamic MR mammography: effects of menopausal status, oral contraceptives, and postmenopausal hormone therapy.
Hegenscheid K; Schmidt CO; Seipel R; Laqua R; Ohlinger R; Hosten N; Puls R
Eur Radiol; 2012 Dec; 22(12):2633-40. PubMed ID: 22772146
[TBL] [Abstract][Full Text] [Related]
19. Repeated surgeries in invasive lobular breast cancer with preoperative MRI: Role of additional carcinoma in situ and background parenchymal enhancement.
Preibsch H; Richter V; Bahrs SD; Hattermann V; Wietek BM; Bier G; Kloth C; Blumenstock G; Hahn M; Staebler A; Nikolaou K; Wiesinger B
Eur J Radiol; 2017 May; 90():181-187. PubMed ID: 28583631
[TBL] [Abstract][Full Text] [Related]
20. Preliminary study: Breast cancers can be well seen on 3T breast MRI with a half-dose of gadobutrol.
Melsaether AN; Kim E; Mema E; Babb J; Kim SG
Clin Imaging; 2019; 58():84-89. PubMed ID: 31279989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
